SCHEMBL26496137

SCHEMBL26496137

COc1cc(N2CCC(N3CCN(CC4CCN(CC5CCC5)CC4)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2N(C)S(C)(=O)=O)n1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 12/20 0.80
▸ MET P08581 2/20 0.80
▸ INSR P06213 9/20 0.64
▸ IGF1R P08069 9/20 0.64
▸ ALK Q9UM73 9/20 0.64
▸ BMPR1B O00238 1/20 0.59
▸ PLK4 O00444 1/20 0.59
▸ STK25 O00506 1/20 0.59
▸ RIOK3 O14730 1/20 0.59
▸ CHEK1 O14757 1/20 0.59
▸ CASK O14936 1/20 0.59
▸ AURKA O14965 1/20 0.59
▸ GAK O14976 1/20 0.59
▸ DCLK1 O15075 1/20 0.59
▸ MUSK O15146 1/20 0.59
▸ EPHB6 O15197 1/20 0.59
▸ PDPK1 O15530 1/20 0.59
▸ MAP3K13 O43283 1/20 0.59
▸ DAPK3 O43293 1/20 0.59
▸ MAP3K7 O43318 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26496135 0.94 EGFR (0.77) EGFRMETINSRIGF1RALK
SCHEMBL25258208 0.93 EGFR (0.79) EGFRMETINSRIGF1RALK
SCHEMBL25308149 0.92 EGFR (0.80) EGFRMETINSRIGF1RALK
SCHEMBL25307921 0.90 EGFR (0.71) EGFRMETINSRIGF1RALK
SCHEMBL25874807 0.90 EGFR (0.72) EGFRMETINSRIGF1RALK
SCHEMBL25306139 0.89 EGFR (0.85) EGFRMETINSRIGF1RALK
SCHEMBL25307926 0.89 EGFR (0.68) EGFRMETINSRIGF1RALK
SCHEMBL25300304 0.89 EGFR (0.68) EGFRMETINSRIGF1RALK
SCHEMBL25305317 0.89 EGFR (0.71) EGFRMETINSRIGF1RALK
SCHEMBL21432183 0.89 EGFR (1.00) EGFRMETINSRIGF1RALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322723-A1 COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF J2H BIOTECH INC. (KR) 2023-10-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322723-A1 COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF EGFR, KRAS, ERBB2 EGFR 1/4885MET 14/4885INSR 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback